Stocks Health care PRPH
OTC · Health careProPhase Labs, Inc. (PRPH)
ProPhase Labs, Inc. brought in $3.8M of revenue over the twelve months to June 30, 2026, down 31.2% from a year earlier. It posted a net loss of $22.5M. In fiscal 2025 capital spending exceeded operating cash flow by $8.3M. At June 30, 2026 it held $20K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 19, 2026.
Watch PRPH in 60 secondsWhat ProPhase Labs, Inc. does
ProPhase Labs, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker PRPH.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $4.3M | -$14.7M | -$1.74 | -$8.3M |
| 2024 | $6.8M | -$53.4M | -$26.68 | -$18.4M |
| 2023 | $35M | -$16.8M | -$10.02 | -$14M |
| 2022 | $122.6M | $18.5M | $10.43 | $24.6M |
| 2021 | $79M | $6.3M | $4.09 | -$17.9M |
| 2020 | $14.5M | -$2.1M | -$1.84 | -$4.3M |
Full financial statements: income, balance sheet and cash flow
Where PRPH ranks in Health care
Dividends
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2023 | n/a | $0 | n/a |
| 2022 | n/a | $9.4M | 51% |
| 2021 | $0.30 | $4.5M | 72% |
| 2019 | n/a | $5.8M | n/a |
| 2018 | n/a | $11.7M | n/a |
Latest SEC filings
What ProPhase Labs, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 19, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 19% to $1M versus the same quarter last year; diluted EPS -$0.22 versus -$1.08.
- August 14, 2026Late quarterly report notice NT 10-Q
- August 6, 2026
- July 9, 2026Quarterly report (amended) 10-Q/A · period to March 31, 2026Revenue fell 18% to $1.2M versus the same quarter last year; diluted EPS -$0.42 versus $1.13.
- July 7, 2026Quarterly report (amended) 10-Q/A · period to March 31, 2026Revenue fell 18% to $1.2M versus the same quarter last year; diluted EPS -$0.42 versus $1.13.
- June 30, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 18% to $1.2M versus the same quarter last year; diluted EPS -$0.42 versus $1.13.
- June 1, 2026Annual report 10-K · period to December 31, 2025Revenue fell 36% to $4.3M versus the prior year; diluted EPS -$1.74 versus -$26.68.
- May 15, 2026Late quarterly report notice NT 10-Q
- March 27, 2026Late annual report notice NT 10-K
- February 13, 2026Other event 8-K
Insider trades
What the people running ProPhase Labs, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Questions about PRPH
What does ProPhase Labs, Inc. do?
ProPhase Labs, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker PRPH.
Is ProPhase Labs, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $22.5M on revenue of $3.8M.
How much revenue does ProPhase Labs, Inc. make?
Over the twelve months to June 30, 2026 ProPhase Labs, Inc. reported revenue of $3.8M. That is 31.2% less than a year earlier.
When did ProPhase Labs, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 19, 2026. It covers the period to June 30, 2026.
Similar companies
Compare PRPH with
Follow PRPH
Get an email when ProPhase Labs, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow PRPH: get an email when it filesWhere the numbers come from
Financial figures are the values ProPhase Labs, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.